Patients with preoperative diagnoses of prostate cancer, urethral stricture, median lobe, neurogenic bladder, or psychological disorders were excluded from the study. Prostate-specific antigen (PSA), International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax), post-void residual (PVR), and quality of life (QoL) were reassessed, and prostate volume was measured at postoperative months 3 and 12. This evidence concerns the gene KLK3 and prostate cancer.